Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
670
Trial Sponsor
Clinical Trial Start Date
2015
0Primary Completion Date
November 25, 2019
0Study Completion Date
November 25, 2019
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Biological0
Intervention Name
MGD0090
Interventional Trial Phase
Phase 10
Participating Facility
Official Name
Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms0
Last Updated
February 8, 2022
0Allocation Type
NA0
Intervention Model
Single Group Assignment0
Masking Type
None (Open Label)0
Study summary
The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely. Assessments will be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics (PD) and to evaluate potential anti-tumor activity of MGD009.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
